K. Ritter

发表

Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.

C. Venot, H. Strobel, D. Lesuisse, 2011, Bioorganic & medicinal chemistry letters.

G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.

C. Buning, Lothar Schwink, K. Ritter, 2016, Journal of medicinal chemistry.

Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.

Hans Matter, Volker Laux, Armin Bauer, 2005, Journal of medicinal chemistry.

A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.

S. Ratnofsky, D. Borhani, D. J. Calderwood, 2004, Bioorganic & medicinal chemistry letters.

Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.

H. Matter, H. Schreuder, V. Laux, 2004, Bioorganic & medicinal chemistry letters.

Probing Factor Xa Protein-Ligand Interactions: Accurate Free Energy Calculations and Experimental Validations of Two Series of High-Affinity Ligands.

H. Matter, P. Lindemann, Svenja Herziger, 2022, Journal of medicinal chemistry.

Anti‐Obesity Drugs (A08)

K. Ritter, 2018 .

Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight.

D. J. Calderwood, K. Ritter, M. Friedman, 2002, Bioorganic & medicinal chemistry letters.

Claisen rearrangement of organotin compounds.

K. Ritter, 1990 .

Synthetic Transformations of Vinyl and Aryl Triflates

K. Ritter, 1994 .

Facile syntheses of 2,4,6-cycloheptatrienyl ketones

M. Hanack, K. Ritter, 1985 .

Biomimetic synthesis of a preclavulone a model

E. Corey, M. Yus, C. Nájera, 1987 .

Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity.

Stefan Güssregen, Hans Matter, Armin Bauer, 2009, Angewandte Chemie.

Synthesen von 2,4,6‐Cycloheptatrien‐1‐yl‐ketonen

M. Hanack, K. Ritter, 1986 .

Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.

H. Matter, H. Schreuder, V. Laux, 2004, Bioorganic & medicinal chemistry letters.

Antidiabetic Drugs (A10)

K. Ritter, 2018 .

1,1-Dioxo-5,6-dihydro-[4,1,2]oxathiazines, a novel class of 11ß-HSD1 inhibitors for the treatment of diabetes.

T. Haack, K. Ritter, S. Güssregen, 2014, Bioorganic & medicinal chemistry letters.

Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes.

Hans Matter, Armin Bauer, Marc Nazaré, 2012, Angewandte Chemie.

ChemInform Abstract: Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck - A Selectivity Insight.

D. J. Calderwood, K. Ritter, M. Friedman, 2002 .

1,1-Dioxo-5,6-dihydro-[4,1,2]oxathiazines, a novel class of 11ß-HSD1 inhibitors for the treatment of diabetes.

T. Haack, K. Ritter, S. Güssregen, 2014, Bioorganic & medicinal chemistry letters.